Risk of New-Diagnosed Atrial Fibrillation After Transient Ischemic Attack.
NT-proBNP
acute ischemic stroke
atrial fibrillation
biomarkers
etiology
transient ischemic attack
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
03
2022
accepted:
07
06
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
2
8
2022
Statut:
epublish
Résumé
Transient ischemic attack (TIA) provides a unique opportunity to optimize secondary preventive treatments to avoid subsequent ischemic stroke (SIS). Although atrial fibrillation (AF) is the leading cause of cardioembolism in IS and anticoagulation prevents stroke recurrence (SR), limited data exists about the risk of new-diagnosed AF (NDAF) after TIA and the consequences of the diagnostic delay. The aim of our study was to determine this risk in a cohort of TIA patients with long-term follow-up. We carried out a prospective cohort study of 723 consecutive TIA patients from January 2006 to June 2010. Median follow-up was 6.5 (5.0-9.6) years. In a subgroup of 204 (28.2%) consecutive patients, a panel of biomarkers was assessed during the first 24 h of the onset of symptoms. Multivariate analyses were performed to find out the associated factors of NDAF. Kaplan-Meier analysis was also performed to analyzed risk of SIS. NDAF was indentified in 116 (16.0%) patients: 42 (36.2%) during admission, 18 (15.5%) within first year, 29 (25%) between one and five years and 27 (23.3%) beyond 5 years. NDAF was associated with sex (female) [hazard ratio (HR) 1.61 (95% CI, 1.07- 2.41)], age [[HR 1.05 (95% CI, 1.03-1.07)], previous ischemic heart disease (IHD) [HR 1.84, (95% CI 1.15-2.97)] and cortical DWI pattern [HR 2.81 (95% CI, 1.87-4.21)]. In the Kaplan-Meier analysis, NT-proBNP ≥ 218.2 pg/ml (log-rank test The risk of NDAF after TIA is clinically relevant. We identified clinical and neuroimaging factors of NDAF. In addition, NT-proBNP was related to NDAF. Our results can be used to evaluate the benefit of long-term cardiac monitoring in selected patients.
Sections du résumé
Background
UNASSIGNED
Transient ischemic attack (TIA) provides a unique opportunity to optimize secondary preventive treatments to avoid subsequent ischemic stroke (SIS). Although atrial fibrillation (AF) is the leading cause of cardioembolism in IS and anticoagulation prevents stroke recurrence (SR), limited data exists about the risk of new-diagnosed AF (NDAF) after TIA and the consequences of the diagnostic delay. The aim of our study was to determine this risk in a cohort of TIA patients with long-term follow-up.
Methods
UNASSIGNED
We carried out a prospective cohort study of 723 consecutive TIA patients from January 2006 to June 2010. Median follow-up was 6.5 (5.0-9.6) years. In a subgroup of 204 (28.2%) consecutive patients, a panel of biomarkers was assessed during the first 24 h of the onset of symptoms. Multivariate analyses were performed to find out the associated factors of NDAF. Kaplan-Meier analysis was also performed to analyzed risk of SIS.
Results
UNASSIGNED
NDAF was indentified in 116 (16.0%) patients: 42 (36.2%) during admission, 18 (15.5%) within first year, 29 (25%) between one and five years and 27 (23.3%) beyond 5 years. NDAF was associated with sex (female) [hazard ratio (HR) 1.61 (95% CI, 1.07- 2.41)], age [[HR 1.05 (95% CI, 1.03-1.07)], previous ischemic heart disease (IHD) [HR 1.84, (95% CI 1.15-2.97)] and cortical DWI pattern [HR 2.81 (95% CI, 1.87-4.21)]. In the Kaplan-Meier analysis, NT-proBNP ≥ 218.2 pg/ml (log-rank test
Conclusion
UNASSIGNED
The risk of NDAF after TIA is clinically relevant. We identified clinical and neuroimaging factors of NDAF. In addition, NT-proBNP was related to NDAF. Our results can be used to evaluate the benefit of long-term cardiac monitoring in selected patients.
Identifiants
pubmed: 35911925
doi: 10.3389/fneur.2022.905304
pmc: PMC9331650
doi:
Types de publication
Journal Article
Langues
eng
Pagination
905304Informations de copyright
Copyright © 2022 Purroy, Vicente-Pascual, Arque, Begue, Farre, Gallego, Gil-Villar, Mauri, Montalà, Pereira, Torres-Querol and Vazquez-Justes.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2018 Jun 07;378(23):2182-2190
pubmed: 29766771
N Engl J Med. 2019 May 16;380(20):1906-1917
pubmed: 31091372
Stroke. 2009 Jun;40(6):2276-93
pubmed: 19423857
Int J Stroke. 2017 Jan;12(1):33-45
pubmed: 27681890
EBioMedicine. 2016 Dec;14:131-138
pubmed: 27843094
Eur J Neurol. 2011 Jan;18(1):121-8
pubmed: 20500525
N Engl J Med. 2018 Sep 06;379(10):986-7
pubmed: 30188630
J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):596-603
pubmed: 23345284
Stroke. 2015 Jun;46(6):1693-5
pubmed: 25931467
Neurology. 2018 Feb 13;90(7):e553-e558
pubmed: 29343466
Eur Stroke J. 2021 Jun;6(2):V
pubmed: 34414306
Stroke. 2016 Oct;47(10):2456-61
pubmed: 27561674
Int J Stroke. 2019 Feb;14(2):207-214
pubmed: 30196789
Lancet. 2007 Jan 27;369(9558):283-92
pubmed: 17258668
Stroke. 2021 Jan;52(2):424-433
pubmed: 33493055
Eur J Neurol. 2014 Apr;21(4):679-83
pubmed: 23800180
Stroke. 2017 Jun;48(6):1495-1500
pubmed: 28487336
JAMA. 2000 Dec 13;284(22):2901-6
pubmed: 11147987
Cerebrovasc Dis. 2008;25(5):457-507
pubmed: 18477843
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Eur Heart J. 2021 Oct 21;42(40):4194
pubmed: 34520521
Stroke. 1990 Apr;21(4):637-76
pubmed: 2326846
Stroke. 2013 Dec;44(12):3357-64
pubmed: 24130137
Ann Neurol. 2006 Sep;60(3):301-13
pubmed: 16912978
Age Ageing. 2007 Nov;36(6):676-80
pubmed: 17656422
Front Neurol. 2020 Dec 08;11:606521
pubmed: 33363511
Cerebrovasc Dis. 2019;47(3-4):151-164
pubmed: 31055571
Stroke. 2006 Feb;37(2):577-617
pubmed: 16432246
Cerebrovasc Dis. 2013;36(1):1-5
pubmed: 23899749
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
Eur Neurol. 2014;71(5-6):313-8
pubmed: 24685765
Circulation. 2019 Nov 26;140(22):1834-1850
pubmed: 31765261
N Engl J Med. 2014 Jun 26;370(26):2467-77
pubmed: 24963566
Stroke. 2020 May;51(5):1396-1403
pubmed: 32252601
Curr Neurol Neurosci Rep. 2018 Aug 8;18(10):66
pubmed: 30090997
N Engl J Med. 2020 May 14;382(20):1933-1941
pubmed: 32402163
Cerebrovasc Dis. 2017;43(1-2):90-98
pubmed: 27992865
J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1138-41
pubmed: 24189453
Stroke. 2015 May;46(5):1187-95
pubmed: 25765726
Nat Rev Neurol. 2017 Sep;13(9):521-532
pubmed: 28731036